Synthesis and anticancer activity of a series of norcantharidin analogues

European Journal of Medicinal Chemistry

Volumn 54, Issue , 2012, Pages 573-581

  Tarleton, Mark ^a   Gilbert, Jayne ^b   Sakoff, Jennette A ^b   McCluskey, Adam ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

Author keywords

Anti cancer; Cantharidin; Focused libraries; Norcantharidin; Synthesis

Indexed keywords

3 (ALLYLOXY)HEXAHYDRO 4,7 EPOXYISOBENZOFURAN 1(3H) ONE; 3 (BUT 2 EN 1 YLOXY)HEXAHYDRO 4,7 XYISOBENZOFURAN 1(3H) ONE; 3 (CYCLOHEXYLOXY)HEXAHYDRO 4,7 EPOXYISOBENZOFURAN 1(3H) ONE; 3 (HEX 5 YN 1 YLOXY)HEXAHYDRO 4,7 EPOXYISOBENZOFURAN 1(3H) ONE; 3 (HEXYLOXY)HEXAHYDRO 4,7 EPOXYISOBENZOFURAN 1(3H) ONE; 3 (OCTYLOXY)HEXAHYDRO 4,7 EPOXYISOBENZOFURAN 1(3H) ONE; 3 (OXIRAN 2 YLMETHOXY)HEXAHYDRO 4,7 EPOXYISOBENZOFURAN 1(3H) ONE; 3 (PENTYLOXY)HEXAHYDRO 4,7 EPOXYISOBENZOFURAN 1(3H) ONE; 3 (TERT BUTOXY)HEXAHYDRO 4,7 EPOXYISOBENZOFURAN 1(3H) ONE; 3 [(3 METHYLOXIRAN 2 YL)METHOXY]HEXAHYDRO 4,7 EPOXYISOBENZOFURAN 1(3H) ONE; 3 BUTOXYHEXAHYDRO 4,7 EPOXYISOBENZOFURAN 1(3H) ONE; 3 ETHOXYHEXAHYDRO 4,7 EPOXYISOBENZOFURAN 1(3H) ONE; 3 HYDROXYHEXAHYDRO 4,7 EPOXYISOBENZOFURAN 1(3H) ONE; 3 ISOPROPOXYHEXAHYDRO 4,7 EPOXYISOBENZOFURAN 1(3H) ONE; 3 PROPAN 3 OLOXYHEXAHYDRO 4,7 EPOXYISOBENZOFURAN 1(3H) ONE; ANTINEOPLASTIC AGENT; FOSTRIECIN; HYDROXYL GROUP; LACTONE; NORCANTHARIDIN; PHOSPHORIC ACID 3 (5 OXO 4,10 DIOXATRICYCLO[5.2.1.0]DEC 3 YLOXY)PROPYL ESTER BIS (2,2,2 TRICHLOROETHYL)ESTER; PHOSPHORIC ACID 3 (5 OXO 4,10 DIOXATRICYCLO[5.2.1.0]DEC 3 YLOXY)PROPYL ESTER DIPHENYL ESTER; PHOSPHORIC ACID DIETHYL ESTER 3 (5 OXO 4,10 DIOXATRICYCLO[5.2.1.0]DEC 3 YLOXY)PROPYL ESTER; PHOSPHORIC ACID MONO [3 (5 OXO 4,10 DIOXATRICYCLO[5.2.1.0]DEC 3 YLOXY)PROPYL]ESTER; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL STRAIN HT29; CYTOTOXICITY; DIASTEREOISOMER; DRUG STRUCTURE; DRUG SYNTHESIS; EPOXIDATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MICROWAVE RADIATION; PROTON NUCLEAR MAGNETIC RESONANCE; TUMOR CELL;

ANTINEOPLASTIC AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY TECHNIQUES, SYNTHETIC; HUMANS; INHIBITORY CONCENTRATION 50;

EID: 84864413863     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.06.010     Document Type: Article

References (30)

1. G.S. Wang J. Ethnopharmacol. 26 1989 147 162
2. M.T. Goldfarb, A.K. Gupta, and W.S. Sawchuk Dermatol. Clin. 9 1991 287 296
3. C.V. Southcott Med. J. Aust. 151 1989 654 659
4. L.C. Nicholls, and D. Teare Br. Med. J. 2 1954 1384 1386
5. X.H. Liu, I. Balzsek, M. Comisso, S. Legras, S. Marion, P. Quittet, A. Anjo, and G.S. Wang Eur. J. Cancer 31A 1995 953 963
6. A. McCluskey, M.C. Bowyer, E. Collins, A.T.R. Sim, J.A. Sakoff, and M.L. Baldwin Bioorg. Med. Chem. Lett. 10 2000 1687 1690
7. Y.-M. Li, and J.E. Casida Proc. Natl. Acad. Sci. U. S. A. 89 1992 11867 11870
8. R.W. Murray Nature 359 1992 599 604
9. S. Wera, and B.A. Hemmings Biochem. J. 311 1995 17 29
10. M. Roberge, C. Tudan, S.M. Hung, K.W. Harder, and F.R. Jirik Cancer Res. 54 1994 6115 6121
11. G.L. Chen, Yang, T.C. Rowe, B.D. Halligan, K.M. Tewey, and L.F. Liu J. Biol. Chem. 259 1984 13560 13566
12. K.M. Tewey, T.C. Rowe, L. Yang, B.D. Hallighan, and L. Liu Science 266 1984 466 468
13. R.S. de Jong, E.G.E. de Vries, S. Meijer, P.E. de Jong, and N.H. Mulder Cancer Chemother. Pharmacol. 42 1998 160 164
14. R.S. de Jong, N.H. Mulder, D.R.A. Uges, D.T. Sleijfer, F.J.P. Hoppener, H.J.M. Groen, P.H.B. Willemse, W.T.A. van der Graaf, and E.G.E. de Vries Br. J. Cancer 79 1999 882 887
15. A. McCluskey, M.A. Keane, L.-M. Mudgee, A.T.R. Sim, J. Sakoff, and R.J. Quinn Eur. J. Med. Chem. 35 2000 957 964
16. I. Bertini, V. Calderone, M. Fragai, C. Luchinat, and E. Talluri J. Med. Chem. 52 2009 4838 4843
17. A. McCluskey, S.P. Ackland, E. Gardiner, M.L. Baldwin, M.C. Bowyer, M.A. Keane, C. Walkom, and J.A. Sakoff Anticancer Drug Des. 16 2001 291 303
18. A. McCluskey, S.P. Ackland, M.C. Bowyer, M.L. Baldwin, J. Garner, C.C. Walkom, and J.A. Sakoff Bioorg. Chem. 31 2003 68 79
19. J.A. Sakoff, I.J. Howitt, S.P. Ackland, and A. McCluskey Cancer Chemother. Pharmacol. 53 2004 225 232
20. M.E. Hart, A.R. Chamberlin, C. Walkom, J.A. Sakoff, and A. McCluskey Bioorg. Med. Chem. Lett. 14 2004 1969 1973
21. T.A. Hill, S.G. Stewart, B. Sauer, J. Gilbert, S.P. Ackland, J.A. Sakoff, and A. McCluskey Bioorg. Med. Chem. Lett. 17 2007 3392 3397
22. T.A. Hill, S.G. Stewart, S.P. Ackland, J. Gilbert, B. Sauer, J.A. Sakoff, and A. McCluskey Bioorg. Med. Chem. 15 2007 6126 6134
23. T.A. Hill, S.G. Stewart, C.P. Gordon, S.P. Ackland, J. Gilbert, B. Sauer, J.A. Sakoff, and A. McCluskey ChemMedChem 3 2008 1878 1892
24. M.J. Robertson, S.G. Stewart, C.P. Gordon, J. Gilbert, J.A. Sakoff, and A. McCluskey Bioorg. Med. Chem. 19 2011 5734 5741
25. L. Deng, and S. Tang Expert Opin. Ther. Pat. 21 2011 1743 1753
26. L. Deng, Z. Yong, W. Tao, J. Shen, and W. Wang J. Heterocycl. Chem. 48 2011 808 813
27. L. Deng, Y. Shen, W. Wang, W. Tao, J. Lv, and C. Wu Lett. Drug Des. Discov. 6 2009 345 352
28. L. Deng, B. Yang, Q. He, and Y. Hu Lett. Drug Des. Discov. 5 2008 346 352
29. J.A. Sakoff, S.P. Ackland, M.L. Baldwin, M.A. Keane, and A. McCluskey Invest. New Drugs 20 2002 1 11
30. A. Thaqi, J.L. Scott, J. Gilbert, J.A. Sakoff, and A. McCluskey Eur. J. Med. Chem. 45 2010 1717 1723